Converge is now affiliated to all 18 Scottish universities, offering a prize fund of $305,000 through four competition-orientated programs.

Toronto's Creative Destruction Lab accelerator network will open its first UK-based location through a partnership with University of Oxford after expanding into the US with NYU in 2018.

CWRU-licensed NervGen Pharma floated at the top of its range on the TSX Venture Exchange, with the proceeds earmarked to push its lead candidate for spinal cord injury into the clinic.

Cystic fibrosis drug developer Respirion Pharmaceuticals has spun out from Telethon Kids Institute with capital from an Australian government-backed initiative.

Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.

A roundup of all the latest news on www.globaluniversityventuring.com for our subscribers.

New York Genome Center-founded Gencove has added $3m from investors including Alexandria Venture Investments to bring its genomics testing kit to new markets.

Based on UCL and Bristol research, Phasecraft is a member of a UK government-backed quantum collaboration driven by both universities together with the Google Quantum AI Lab.

The medical research services provider collected funding from investors including Cash Capital, an investment arm of CAS which previously backed a series A.

IU Philanthropic Venture Fund was among the investors in the contact centre platform creator's round, which will help grow the business through recruitment and product development.